Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bristol Myers

The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022

Bristol Myers Squibb expects a $10 billion or double-digit decline from its generics-facing products. BMY stock fell Wednesday.

Investors Business Daily

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why

DECK is getting closer to the top of its large cup base.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

New York Judge Denies Bristol Myers Claim To Dismiss Lawsuit Over Delayed Cancer Drug Approval: Reuters

According to a Reuters report, U.S. District Judge Jesse Furman in Manhattan refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co (NYSE:BMY) of delaying its Breyanzi cancer drug to avoid payments to former Celgene shareholders. The judge rejected Bristol Myers' claim that it was never properly notified about its alleged default…

Benzinga

Dow Jones Futures: New Market Rally Struggles For Direction; 5 Stocks Near Buy Points

The market rally rebounded from losses but gains faded. Five stocks from a hot sector are near buy points.

Investors Business Daily

IBD Stock Of The Day: Bristol Myers Eyes Breakout After $4.1 Billion Buyout

Bristol Myers Squibb is the IBD Stock Of The Day as BMY stock bounds off its 50-day line, presenting investors with an early entry.

Investors Business Daily

Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX)

Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Tribune News Service

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?

Turning Point Therapeutics snagged a $4.1 billion offer from Bristol Myers Squibb on Friday, and TPTX stock more than doubled.

Investors Business Daily

BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced interim Phase 1 data from healthy volunteers, supporting the development of BBP-671 for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias. BBP-671 is being developed as a potential therapy for diseases in which coenzyme-A (CoA) metabolism is deficient, including PKAN, propionic acidemia (PA), and methylmalonic acidemia (MMA).…

Benzinga

Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer

Bristol Myers Squibb & Co's (NYSE:BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in urothelial carcinoma did not meet the primary endpoint of overall survival (OS) at the final analysis. The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma…

Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Bristol Myers Takes Machete To 2022 Outlook As Generics Slam Revlimid, Abraxane

Bristol Myers Squibb cut its 2022 guidance Friday amid patent losses and Revlimid erosion. In response, BMY stock tumbled.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Bristol Myers Q1 Earnings Surpass Street Expectations, Lowers FY22 Guidance

Bristol-Myers Squibb Co (NYSE:BMY) has posted Q1 revenues of $11.65 billion, an increase of 5% Y/Y (7% constant currency), beating the consensus of $11.36 billion. Eliquis, Opdivo, cell therapy products, and Reblozyl drove sales growth. Eliquis sales increased 11% to $3.21 billion, Opdivo sales increased 12% to $1.92 billion, and Yervoy sales…

Investors Business Daily

Dow Jones Falls, Nasdaq Skids On Amazon, AbbVie; Tesla Rises On Elon Musk Move

Stocks fell Friday as Amazon and AbbVie tumbled on earnings. Elon Musk disclosed Tesla stock sales.

Benzinga

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring

Nektar Therapeutics (NASDAQ:NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team. Dimitry Nuyten, Nektar's Chief Medical Officer, will step down from his position following June 2022. He will be succeeded by Brian Kotzin, Nektar's Head of…

Benzinga

Bristol Myers' Neoadjuvant Opdivo/Chemo Therapy Yet To Reach Overall Survival Endpoint In Early-Stage Lung Cancer

Bristol Myers Squibb Co (NYSE: BMY) announced results from the Phase 3 CheckMate -816 trial in resectable non-small cell lung cancer (NSCLC).

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag

The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.

Benzinga

Bristol Myers Squibb Embarks Oncology Pact With Volastra Therapeutics

Bristol Myers Squibb Co (NYSE: BMY) is pairing with New York-based biotech Volastra Therapeutics.

Investors Business Daily

Nektar Therapeutics Loses 60% Its Value As Bristol Myers-Paired Melanoma Test Flops

Adding Nektar's most advanced drug to Bristol Myers' Opdivo didn't improve outcomes for melanoma patients — leading NKTR stock to crash Monday.

Investors Business Daily

These Four Exceptions Prove You Can Still Make Money In Medical Stocks

Bristol Myers, Eli Lilly and two others prove you can still make money investing in medical stocks — if you know where to look.

Benzinga

Bristol Myers' Opdivo Under Priority FDA Review In Neoadjuvant Lung Cancer Setting

The

Benzinga

Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy

Bristol Myers Squibb Co's (NYSE: BMY) VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM)

Investors Business Daily

Bristol Myers Expects $10.5 Billion Shortfall This Year As Generics Loom

Bristol Myers offered strong sales guidance Friday, and BMY stock rose despite looming competition for two of its biggest cancer drugs.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.